drugset / Trial / NCT07562152
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Timeline
- Start
- 2026-06
- Primary completion
- 2028-06
- Completion
- 2029-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atebimetinib | Unknown | — | Oral |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |